Perrigo Price to Free Cash Flow Ratio 2010-2024 | PRGO
Historical price to free cash flow ratio values for Perrigo (PRGO) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Perrigo Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2024-11-21 | 27.08 | 19.87 | |
| 2024-09-30 | 26.23 | $1.36 | 19.25 |
| 2024-06-30 | 25.44 | $1.69 | 15.07 |
| 2024-03-31 | 31.89 | $2.08 | 15.32 |
| 2023-12-31 | 31.58 | $2.25 | 14.07 |
| 2023-09-30 | 31.08 | $2.09 | 14.87 |
| 2023-06-30 | 32.77 | $1.51 | 21.71 |
| 2023-03-31 | 34.33 | $0.93 | 36.91 |
| 2022-12-31 | 32.38 | $1.57 | 20.65 |
| 2022-09-30 | 33.60 | $-0.72 | 0.00 |
| 2022-06-30 | 37.96 | $1.44 | 26.32 |
| 2022-03-31 | 35.73 | $-2.75 | 0.00 |
| 2021-12-31 | 35.90 | $-3.03 | 0.00 |
| 2021-09-30 | 43.39 | $-1.80 | 0.00 |
| 2021-06-30 | 41.79 | $-2.13 | 0.00 |
| 2020-12-31 | 40.32 | $3.40 | 11.88 |
| 2020-09-30 | 41.20 | $5.23 | 7.88 |
| 2020-06-30 | 49.39 | $4.76 | 10.38 |
| 2020-03-31 | 42.80 | $3.60 | 11.89 |
| 2019-12-31 | 45.78 | $2.81 | 16.27 |
| 2021-03-31 | 36.70 | $1.18 | 30.98 |
| 2019-09-30 | 49.32 | $2.58 | 19.13 |
| 2019-06-30 | 41.84 | $2.71 | 15.45 |
| 2019-03-31 | 42.11 | $2.96 | 14.22 |
| 2018-12-31 | 33.75 | $3.55 | 9.52 |
| 2018-09-30 | 61.66 | $3.76 | 16.42 |
| 2018-06-30 | 63.34 | $4.14 | 15.28 |
| 2018-03-31 | 72.21 | $4.20 | 17.18 |
| 2017-12-31 | 75.34 | $4.28 | 17.60 |
| 2017-09-30 | 73.04 | $4.30 | 16.98 |
| 2017-06-30 | 65.02 | $4.36 | 14.93 |
| 2017-03-31 | 57.04 | $4.58 | 12.44 |
| 2016-12-31 | 71.35 | $3.83 | 18.63 |
| 2016-09-30 | 79.02 | $0.05 | 1606.16 |
| 2016-06-30 | 77.47 | $0.99 | 77.89 |
| 2016-03-31 | 109.15 | $1.29 | 84.74 |
| 2015-12-31 | 123.31 | $2.69 | 45.76 |
| 2015-09-30 | 133.91 | $6.40 | 20.92 |
| 2015-03-31 | 140.78 | $2.03 | 69.33 |
| 2014-12-31 | 142.03 | $3.07 | 46.29 |
| 2014-09-30 | 127.53 | $2.00 | 63.91 |
| 2014-06-30 | 123.68 | $1.44 | 85.66 |
| 2014-03-31 | 131.13 | $0.18 | 711.50 |
| 2013-12-31 | 130.03 | $1.44 | 90.06 |
| 2013-09-30 | 104.48 | $2.36 | 44.29 |
| 2013-06-30 | 102.39 | $2.01 | 50.84 |
| 2013-03-31 | 100.40 | $2.96 | 33.87 |
| 2012-12-31 | 87.89 | $2.01 | 43.64 |
| 2012-09-30 | 98.06 | $1.69 | 57.91 |
| 2012-06-30 | 99.47 | $1.75 | 56.88 |
| 2012-03-31 | 87.08 | $2.20 | 39.61 |
| 2011-12-31 | 81.95 | $1.75 | 46.86 |
| 2011-09-30 | 81.71 | $1.53 | 53.53 |
| 2011-06-30 | 73.88 | $0.99 | 74.83 |
| 2011-03-31 | 66.81 | $0.93 | 71.78 |
| 2010-12-31 | 53.15 | $0.99 | 53.83 |
| 2010-09-30 | 53.84 | $0.95 | 56.38 |
| 2010-06-30 | 49.47 | $1.43 | 34.63 |
| 2010-03-31 | 49.12 | $2.69 | 18.27 |
| 2009-12-31 | 33.28 | $1.43 | 23.30 |
| 2009-09-30 | 28.35 | $0.31 | 91.82 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $3.830B | $4.656B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $204.249B | 26.05 |
| Stryker (SYK) | United States | $146.711B | 33.06 |
| Boston Scientific (BSX) | United States | $132.644B | 38.14 |
| EssilorLuxottica (ESLOY) | France | $112.106B | 0.00 |
| Medtronic (MDT) | Ireland | $110.562B | 16.42 |
| Haleon (HLN) | United Kingdom | $43.682B | 28.38 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.166B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $37.665B | 19.54 |
| ResMed (RMD) | United States | $35.786B | 29.41 |
| Terumo (TRUMY) | Japan | $29.739B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $24.805B | 18.99 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.942B | 13.97 |
| Insulet (PODD) | United States | $18.443B | 73.44 |
| Baxter (BAX) | United States | $16.957B | 11.03 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.065B | 0.00 |
| BellRing Brands (BRBR) | United States | $10.158B | 40.72 |
| Bio-Rad Laboratories (BIO) | United States | $9.320B | 31.68 |
| Demant (WILYY) | Denmark | $8.342B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.294B | 14.62 |
| TG Therapeutics (TGTX) | United States | $5.459B | 0.00 |
| Haemonetics (HAE) | United States | $4.297B | 20.97 |
| Prestige Consumer Healthcare (PBH) | United States | $4.192B | 20.85 |
| ICU Medical (ICUI) | United States | $4.125B | 39.27 |
| Envista Holdings (NVST) | United States | $3.697B | 27.54 |
| Neogen (NEOG) | United States | $3.246B | 37.45 |
| Agios Pharmaceuticals (AGIO) | United States | $3.175B | 0.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.841B | 18.22 |
| QuidelOrtho (QDEL) | United States | $2.700B | 17.38 |
| LeMaitre Vascular (LMAT) | United States | $2.428B | 59.00 |
| Warby Parker (WRBY) | United States | $2.349B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.913B | 33.48 |
| AtriCure (ATRC) | United States | $1.742B | 0.00 |
| InMode (INMD) | Israel | $1.597B | 9.61 |
| AdaptHealth (AHCO) | United States | $1.326B | 9.48 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.318B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.267B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.207B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.962B | 16.96 |
| Owens & Minor (OMI) | United States | $0.952B | 7.44 |
| CeriBell (CBLL) | United States | $0.943B | 0.00 |
| National Vision Holdings (EYE) | United States | $0.918B | 30.68 |
| Capricor Therapeutics (CAPR) | United States | $0.847B | 0.00 |
| Evolus (EOLS) | United States | $0.798B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.684B | 30.25 |
| Omeros (OMER) | United States | $0.632B | 0.00 |
| Surmodics (SRDX) | United States | $0.563B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.533B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.522B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.468B | 0.00 |
| Quanterix (QTRX) | United States | $0.451B | 0.00 |
| ZimVie (ZIMV) | United States | $0.391B | 32.95 |
| Valneva SE (VALN) | France | $0.360B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.341B | 32.41 |
| Cerus (CERS) | United States | $0.332B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.330B | 0.00 |
| Biote (BTMD) | United States | $0.325B | 7.12 |
| OraSure Technologies (OSUR) | United States | $0.289B | 19.40 |
| Zynex (ZYXI) | United States | $0.263B | 55.07 |
| Aurora Cannabis (ACB) | Canada | $0.238B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.225B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.221B | 15.29 |
| High Tide (HITI) | Canada | $0.213B | 88.33 |
| MacroGenics (MGNX) | United States | $0.203B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.188B | 2.64 |
| Brainsway (BWAY) | Israel | $0.167B | 100.00 |
| Organigram Holdings (OGI) | Canada | $0.166B | 0.00 |
| Jin Medical (ZJYL) | China | $0.164B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.160B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.149B | 18.67 |
| TriSalus Life Sciences (TLSI) | United States | $0.138B | 0.00 |
| Fonar (FONR) | United States | $0.104B | 11.74 |
| Quipt Home Medical (QIPT) | United States | $0.104B | 0.00 |
| Veru (VERU) | United States | $0.099B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.094B | 23.40 |
| Ayr Wellness (AYRWF) | United States | $0.077B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.073B | 37.50 |
| Exagen (XGN) | United States | $0.072B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.065B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| InterCure (INCR) | Israel | $0.062B | 0.00 |
| Modular Medical (MODD) | United States | $0.058B | 0.00 |
| MariMed (MRMD) | United States | $0.057B | 0.00 |
| Apyx Medical (APYX) | United States | $0.054B | 0.00 |
| Safety Shot (SHOT) | United States | $0.051B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.050B | 0.00 |
| ImmuCell (ICCC) | United States | $0.033B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.028B | 0.00 |
| Flora Growth (FLGC) | United States | $0.019B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.018B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.016B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.002B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 12.83 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |